About Neurexin-2-beta
Neurexin-2-beta (NRXN2) is a protein
from Homo sapiens identified by UniProt accession
P58401, 666 residues long.
MolForge cross-references it against 0 known binders and
141 disease associations.
Target properties
| Protein name | Neurexin-2-beta |
|---|
| UniProt accession | P58401 |
|---|
| Gene | NRXN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 666 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (141)
Diseases linked to this target (Open Targets).
- autism · score 0.48
- Autism · score 0.47
- uric acid measurement · score 0.37
- body mass index · score 0.32
- urate measurement · score 0.31
- attention deficit hyperactivity disorder · score 0.27
- smoking status measurement · score 0.25
- substance abuse · score 0.25
- antisocial behaviour measurement · score 0.25
- renal system measurement · score 0.24
Amino-acid sequence (666 residues)
MPPGGSGPGG CPRRPPALAG PLPPPPPPPP PPLLPLLPLL LLLLLGAAEG ARVSSSLSTT HHVHHFHSKH GTVPIAINRM PFLTRGGHAG TTYIFGKGGA LITYTWPPND RPSTRMDRLA VGFSTHQRSA VLVRVDSASG LGDYLQLHID QGTVGVIFNV GTDDITIDEP NAIVSDGKYH VVRFTRSGGN ATLQVDSWPV NERYPAGNFD NERLAIARQR IPYRLGRVVD EWLLDKGRQL TIFNSQAAIK IGGRDQGRPF QGQVSGLYYN GLKVLALAAE SDPNVRTEGH LRLVGEGPSV LLSAETTATT LLADMATTIM ETTTTMATTT TRRGRSPTLR DSTTQNTDDL LVASAECPSD DEDLEECEPS TGGELILPII TEDSLDPPPV ATRSPFVPPP PTFYPFLTGV GATQDTLPPP AARRPPSGGP CQAERDDSDC EEPIEASGFA SGEVFDSSLP PTDDEDFYTT FPLVTDRTTL LSPRKPAPRP NLRTDGATGA PGVLFAPSAP APNLPAGKMN HRDPLQPLLE NPPLGPGAPT SFEPRRPPPL RPGVTSAPGF PHLPTANPTG PGERGPPGAV EVIRESSSTT GMVVGIVAAA ALCILILLYA MYKYRNRDEG SYQVDQSRNY ISNSAQSNGA VVKEKAPAAP KTPSKAKKNK DKEYYV
Explore Neurexin-2-beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets